<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00152464</url>
  </required_header>
  <id_info>
    <org_study_id>A00309</org_study_id>
    <nct_id>NCT00152464</nct_id>
  </id_info>
  <brief_title>Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)</brief_title>
  <official_title>The Early Prevention of Asthma in Atopic Children (EPAAC™) Study. A Multi-country, Double Blind, Placebo (PLC) Controlled, Randomized, Parallel Group Trial: Evaluation of the Efficacy and Safety of Levocetirizine (LCTZ) (5 mg/ml Oral Drops -0.125 mg/kg b.w. b.i.d.) Administered for 18 Months in Preventing the Onset of Asthma in 12 to 24 Months Old Children Who Suffer From Atopic Dermatitis and Are Sensitized to Grass Pollen and / or House Dust Mite Allergens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Early Prevention of Asthma in Atopic Children (EPAAC™). 24 months study to evaluate the
      efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in 12 to 24
      months old children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2002</start_date>
  <completion_date type="Actual">March 15, 2006</completion_date>
  <primary_completion_date type="Actual">March 15, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Onset of Asthma During the Treatment Period</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The time to onset of asthma was defined as the period elapsed between the randomization visit (V2) and the date of onset of asthma.
Instead of the median the first Quartile is reported since the median (50%) was not reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Symptoms of Either Wheezing or Nocturnal Cough</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am and each wheezing event occurring at any time together with the treatment for these symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Symptoms of Wheezing</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The caring person was to note on the diary card each each wheezing event occurring at any time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With Symptoms of Nocturnal Cough</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Using Asthma Medication</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days of Use of Asthma Medication</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Using Medication for Atopic Dermatitis</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The following medications for Atopic Dermatitis were taken into consideration: Topical corticosteroids/ Local Steroids Class A, non‐steroidal anti‐inflammatory (NSAI) creams, tar/ Local Steroids Class B/ Local Steroids Class C/ Topical tacrolimus/ Topical pimecrolimus/ Systemic H1 anti-histamines/ Local antibiotics or antiseptics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days of Use of Medication for Atopic Dermatitis</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>The following medications for Atopic Dermatitis were taken into consideration: Emollients, local antihistamines; Local steroids class (LSC) A, non‐steroidal anti‐inflammatory (NSAI) creams, tar; Local steroids class B; Local steroids class C; Local antibiotics or antiseptics; Oral H1 anti-histamines (a-h); Local antibiotics (ABs) or antiseptics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Urticaria</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episodes of Urticaria Per Subject</measure>
    <time_frame>During the treatment period (18 months)</time_frame>
    <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">514</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Levocetirizine (LCTZ)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (PBO)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo was administered as oral drops twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Oral drops Route of administration: Oral use</description>
    <arm_group_label>Placebo (PBO)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocetirizine</intervention_name>
    <description>Pharmaceutical form: Oral drops Concentration: 5 mg/ml Route of administration: Oral use</description>
    <arm_group_label>Levocetirizine (LCTZ)</arm_group_label>
    <other_name>Xyzal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria which must be verified during screening visit (V1):

          -  Children of either sex aged between 12 and 24 months

          -  Subjects suffering from symptoms of Atopic Dermatitis (AD) lasting cumulatively for at
             least 2 months since birth

          -  Modified Severity Scoring of Atopic Dermatitis (SCORAD) Index &gt;= 10

          -  Subjects whose biological mother or father, or one sibling has a well-documented
             history of atopy (AD, allergic rhinitis or asthma)

        Inclusion criteria which must be verified during randomization (V2):

          -  Results of the Radio-allergosorbant (RAST) test for grass pollen (GP) and house dust
             mite (HDM) are available and Immunoglobulin E (IgE) level against GP &gt;= 0.35 kUA/l
             and/or IgE level against HDM ≥ 0.35 kUA/l

          -  Safety laboratory results are within the normal range of the central laboratory or
             considered as not clinically significant or study disease related by the Investigator

        Exclusion Criteria:

        Exclusion criteria to verify at screening visit (V1):

        Are to be excluded from the participation in the study, those children who

          -  Have height or weight below the 5th percentile

          -  Have experienced at least one episode of wheezing when aged 6 months or over

          -  Have suffered at age 6 months or over, from at least one nocturnal cough episode
             consisting of 3 (or more) consecutive nights resulting in sleep disturbances in a
             clinical setting where asthma is likely and other conditions have been excluded

          -  Have chronic pulmonary diseases of any type, such as, but not limited to, cystic
             fibrosis, or any cranio-facial abnormality, e.g., cleft palate

          -  Have a personal history of sleep apnea or who have siblings with a history of sleep
             apnea

          -  Are treated with any immunomodulator medication such as, e.g., cyclosporin,
             cyclophosphamide or FK 506 (Tacrolimus)

          -  Have received or are receiving allergen - specific immunotherapy

          -  Suffer from concomitant dermatological disease/condition other than atopic dermatitis,
             that might interfere with the evaluation of the clinical response for atopic
             dermatitis

          -  Have an insufficient wash-out period for the following medications:

               -  Intranasal or systemic antihistamines: 3 days,

               -  Intranasal or systemic decongestants: 3 days,

               -  Loratadine, Desloratadine: 10 days,

               -  Chromones: 2 weeks,

               -  Oral corticosteroids: 1 month,

               -  Chronic use (i.e. cumulatively up to 2 weeks within the last 3 months) of
                  inhaled/intranasal corticosteroids: 1 month,

               -  Ketotifen: 1 month,

               -  Astemizole: 6 weeks

          -  Have been treated with any antihistamine, including ketotifen, with daily intake for
             more than 2 consecutive months in the last 6 months before screening

        Subject Exclusion criteria to verify at randomization visit (V2):

        • Intake of any prohibited medication listed above during the selection period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://www.ucb.com/_up/ucb_com_patients/documents/A00309_CSS_20070803.pdf</url>
    <description>Clinical Study Summary on UCB.com</description>
  </link>
  <link>
    <url>http://products.sanofi-aventis.us/xyzal/xyzal.pdf</url>
    <description>Product Information</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2005</study_first_posted>
  <results_first_submitted>October 10, 2017</results_first_submitted>
  <results_first_submitted_qc>August 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EPAAC</keyword>
  <keyword>Atopic children</keyword>
  <keyword>Asthma</keyword>
  <keyword>XYZAL</keyword>
  <keyword>Levocetirizine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levocetirizine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study started to enroll patients in March 2002 and concluded in March 2006.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Intent-to-treat (ITT) population. 514 subjects were initially randomized, 4 subjects withdrew consent before first study drug intake.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo (PBO)</title>
          <description>Placebo was administered as oral drops twice daily.</description>
        </group>
        <group group_id="P2">
          <title>Levocetirizine (LCTZ)</title>
          <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="255"/>
                <participants group_id="P2" count="255"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Atopic dermatitis poorly controlled</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eczema deterioration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parent decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eczema poorly controlled</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient relocated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Intention-to-Treat (ITT) population.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo (PBO)</title>
          <description>Placebo was administered as oral drops twice daily.</description>
        </group>
        <group group_id="B2">
          <title>Levocetirizine (LCTZ)</title>
          <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
        </group>
        <group group_id="B3">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="255"/>
            <count group_id="B2" value="255"/>
            <count group_id="B3" value="510"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="255"/>
                    <measurement group_id="B2" value="255"/>
                    <measurement group_id="B3" value="510"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.42" spread="3.86"/>
                    <measurement group_id="B2" value="19.28" spread="3.94"/>
                    <measurement group_id="B3" value="19.35" spread="3.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Onset of Asthma During the Treatment Period</title>
        <description>The time to onset of asthma was defined as the period elapsed between the randomization visit (V2) and the date of onset of asthma.
Instead of the median the first Quartile is reported since the median (50%) was not reached.</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Onset of Asthma During the Treatment Period</title>
          <description>The time to onset of asthma was defined as the period elapsed between the randomization visit (V2) and the date of onset of asthma.
Instead of the median the first Quartile is reported since the median (50%) was not reached.</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="9.5" upper_limit="NA">Median not reached due to insufficient number of events.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="10.3" upper_limit="NA">Median not reached due to insufficient number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.991</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.338</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Symptoms of Either Wheezing or Nocturnal Cough</title>
        <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am and each wheezing event occurring at any time together with the treatment for these symptoms.</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Symptoms of Either Wheezing or Nocturnal Cough</title>
          <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am and each wheezing event occurring at any time together with the treatment for these symptoms.</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="6.26"/>
                    <measurement group_id="O2" value="2.85" spread="4.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Symptoms of Wheezing</title>
        <description>The caring person was to note on the diary card each each wheezing event occurring at any time.</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Symptoms of Wheezing</title>
          <description>The caring person was to note on the diary card each each wheezing event occurring at any time.</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="3.00"/>
                    <measurement group_id="O2" value="0.88" spread="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With Symptoms of Nocturnal Cough</title>
        <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With Symptoms of Nocturnal Cough</title>
          <description>The caring person was to note on the diary card each nocturnal cough event with sleep disturbances occurring from 7:00 pm to 7:00 am</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="5.24"/>
                    <measurement group_id="O2" value="2.33" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Using Asthma Medication</title>
        <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Using Asthma Medication</title>
          <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta 2 Mimetics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cromoglycates</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled Corticoids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8"/>
                    <measurement group_id="O2" value="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Corticoids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukotriene antagonists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days of Use of Asthma Medication</title>
        <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>255 subject were included in the Intention-to-treat (ITT) set. Number of participants analyzed is given for each individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days of Use of Asthma Medication</title>
          <description>The following asthma medications were taken into consideration: Beta 2-mimetics, cromoglycates, inhaled corticoids, systemic corticoids, leukotriene antagonists</description>
          <population>255 subject were included in the Intention-to-treat (ITT) set. Number of participants analyzed is given for each individual category.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta 2 Mimetics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.36" spread="9.31"/>
                    <measurement group_id="O2" value="1.37" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cromoglycates</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.37"/>
                    <measurement group_id="O2" value="0.09" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inhaled Corticoids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" spread="12.03"/>
                    <measurement group_id="O2" value="1.98" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Corticoids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="254"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="1.02"/>
                    <measurement group_id="O2" value="0.13" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukotriene antagonists</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="2.19"/>
                    <measurement group_id="O2" value="0.34" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Using Medication for Atopic Dermatitis</title>
        <description>The following medications for Atopic Dermatitis were taken into consideration: Topical corticosteroids/ Local Steroids Class A, non‐steroidal anti‐inflammatory (NSAI) creams, tar/ Local Steroids Class B/ Local Steroids Class C/ Topical tacrolimus/ Topical pimecrolimus/ Systemic H1 anti-histamines/ Local antibiotics or antiseptics</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Using Medication for Atopic Dermatitis</title>
          <description>The following medications for Atopic Dermatitis were taken into consideration: Topical corticosteroids/ Local Steroids Class A, non‐steroidal anti‐inflammatory (NSAI) creams, tar/ Local Steroids Class B/ Local Steroids Class C/ Topical tacrolimus/ Topical pimecrolimus/ Systemic H1 anti-histamines/ Local antibiotics or antiseptics</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Topical corticosteroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.6"/>
                    <measurement group_id="O2" value="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Steroids Class A, NSAI creams, tar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Steroids Class B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Steroids Class C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7"/>
                    <measurement group_id="O2" value="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topical tacrolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topical pimecrolimus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic H1 anti-histamines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0"/>
                    <measurement group_id="O2" value="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local antibiotics or antiseptics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9"/>
                    <measurement group_id="O2" value="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days of Use of Medication for Atopic Dermatitis</title>
        <description>The following medications for Atopic Dermatitis were taken into consideration: Emollients, local antihistamines; Local steroids class (LSC) A, non‐steroidal anti‐inflammatory (NSAI) creams, tar; Local steroids class B; Local steroids class C; Local antibiotics or antiseptics; Oral H1 anti-histamines (a-h); Local antibiotics (ABs) or antiseptics</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>255 subject were included in the Intention-to-treat (ITT) set. Number of participants analyzed is given for each individual category.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days of Use of Medication for Atopic Dermatitis</title>
          <description>The following medications for Atopic Dermatitis were taken into consideration: Emollients, local antihistamines; Local steroids class (LSC) A, non‐steroidal anti‐inflammatory (NSAI) creams, tar; Local steroids class B; Local steroids class C; Local antibiotics or antiseptics; Oral H1 anti-histamines (a-h); Local antibiotics (ABs) or antiseptics</description>
          <population>255 subject were included in the Intention-to-treat (ITT) set. Number of participants analyzed is given for each individual category.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Topical corticosteroids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.42" spread="42.96"/>
                    <measurement group_id="O2" value="31.84" spread="42.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSC A, NSAI creams, tar</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="238"/>
                    <count group_id="O2" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.40" spread="33.69"/>
                    <measurement group_id="O2" value="18.64" spread="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSC B</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="240"/>
                    <count group_id="O2" value="245"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.23" spread="32.19"/>
                    <measurement group_id="O2" value="12.30" spread="30.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LSC C</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" spread="24.98"/>
                    <measurement group_id="O2" value="8.27" spread="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topical tacrolimus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="5.41"/>
                    <measurement group_id="O2" value="0.02" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Topical pimecrolimus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="255"/>
                    <count group_id="O2" value="254"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="5.62"/>
                    <measurement group_id="O2" value="0.31" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic H1 a-h</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                    <count group_id="O2" value="252"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="14.28"/>
                    <measurement group_id="O2" value="1.95" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local ABs or antiseptics</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="15.00"/>
                    <measurement group_id="O2" value="2.63" spread="15.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Urticaria</title>
        <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Urticaria</title>
          <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6"/>
                    <measurement group_id="O2" value="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episodes of Urticaria Per Subject</title>
        <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
        <time_frame>During the treatment period (18 months)</time_frame>
        <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo (PBO)</title>
            <description>Placebo was administered as oral drops twice daily.</description>
          </group>
          <group group_id="O2">
            <title>Levocetirizine (LCTZ)</title>
            <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episodes of Urticaria Per Subject</title>
          <description>Urticaria was defined as typical hives or areas of skin swelling, redness and itching distinctly different from the child's usual inflamed skin lesions of Atopic Dermatitis (AD), associated with an infection or food allergen ingestion/contact or other trigger.</description>
          <population>Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</population>
          <units>Number of episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="255"/>
                <count group_id="O2" value="255"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="4.05"/>
                    <measurement group_id="O2" value="0.71" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Visit 1 until during the treatment phase (up to month 18).</time_frame>
      <desc>Adverse Events refer to the Intention-to-treat (ITT) population, consisting of all randomized subjects who took at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (PBO)</title>
          <description>Placebo was administered as oral drops twice daily.</description>
        </group>
        <group group_id="E2">
          <title>Levocetirizine (LCTZ)</title>
          <description>0.125 mg/kg of Levocetirizine (LCTZ) were administered as oral drops twice daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA8.0">Patent ductus arteriosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Eczema infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Haemophilus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="239" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="131" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="255"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="255"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="255"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844 599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

